Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Pharmacists ‘using personal finances and remortgaging to keep businesses afloat’

It comes as a survey found almost four in 10 pharmacies are unable to pay bills for medication on time.

Evening Standard

Nvidia Q2 Preview: 'Saying This Is The Most Important Stock In The World Is An Understatement' (CORRECTED)

CORRECTION: Nvidia’s stock price in the price action section was incorrect. It has been corrected/updated.

Benzinga

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.

Benzinga

Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Shares of Serina Therapeutics Inc (NYSE:SER) rose sharply in pre-market trading after the company announced the FDA has provided written feedback supporting the advancement of SER-252.

Benzinga

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Benzinga

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Valneva SE (NASDAQ:VALN) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.

Benzinga

Streeting vows not to let drug firms ‘rip off’ taxpayers after pricing row

The Health Secretary on Friday left talks with the pharmaceuticals sector after both sides failed to agree changes to a drug pricing deal.

Evening Standard

What is the row between Wes Streeting and pharmaceutical companies about?

Health secretary has accused firms of being ‘shortsighted’ during dispute over terms for provision of drugs to the NHS

The Guardian - UK

Wes Streeting criticises ‘shortsighted’ drug firms for rejecting pricing offer

Exclusive: Health secretary says he will not let patients be ‘ripped off’ by pharmaceutical companies amid standoff

The Guardian - UK

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Breaking the Bottleneck: How Verseon is Rewriting the Future of Drug Discovery Beyond Pharma's Limits

Verseon is transforming drug discovery with physics-based design, breaking pharma's limits to deliver safer, faster treatments across major diseases.

Benzinga

UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System

Drug pricing talks between the U.K. government and pharmaceutical companies collapsed Friday, with industry leaders warning the standoff could deter investment. Health Secretary Wes Streeting described the government's offer as "unprecedented," but drugmakers argued that it still imposed excessive costs and requested to negotiate directly with Prime Minister Keir Starmer.

International Business Times UK

Fury as Tech CEO Sues Uber After Being Assaulted by Illegal Immigrant Driver — Then Losing His Account

Biotech CEO Bryan Kobel sues Uber after allegedly being brutally assaulted by an undocumented Uber driver who denied his service dog, leaving him with serious injuries and prompting scrutiny of Uber's driver vetting.

The Guardian - UK

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Drugmakers reject health secretary’s latest offer, meaning ‘unsustainable’ rebate scheme will stay in place

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

Tharimmune (THAR) Shares Skyrocket On Promising Opioid Countermeasure Data

Shares of Tharimmune Inc (NASDAQ:THAR) are surging Thursday afternoon after the company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104.

Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

5 Healthcare Stocks On Fire This Week

Five healthcare stocks have emerged as standout performers, posting remarkable week-on-week momentum gains according to the latest Benzinga Edge Ranking report.

Benzinga

Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Shares of Nordson Corporation (NASDAQ:NDSN) rose sharply in pre-market trading after the company reported better-than-expected third-quarter results.

Benzinga

Tharimmune Rockets 42% After Hours — Adding To Stunning 206% Daytime Rally: What's Going On?

Tharimmune Inc. (NASDAQ:THAR) jumped 42.06% to $5.10 in after-hours trading on Wednesday following positive pharmacokinetic simulation results for its lead drug candidate TH104, designed to prevent respiratory depression from fentanyl exposure.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.